To date, effective anti-PD-1/PD-L1 immunotherapy for pancreatic cancer has been limited to patients with mismatch repair deficiency and high TMB, representing only 1%-2% of patients with pancreatic cancer.28 This evidence concerns the gene CD274 and pancreatic neoplasm.